BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28953404)

  • 1. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
    El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
    Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
    Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
    Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.
    Choi JY; Fuerst R; Knapinska AM; Taylor AB; Smith L; Cao X; Hart PJ; Fields GB; Roush WR
    J Med Chem; 2017 Jul; 60(13):5816-5825. PubMed ID: 28653849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
    Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13.
    Agamennone M; Belov DS; Laghezza A; Ivanov VN; Novoselov AM; Andreev IA; Ratmanova NK; Altieri A; Tortorella P; Kurkin AV
    ChemMedChem; 2016 Sep; 11(17):1892-8. PubMed ID: 27418256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
    Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
    Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Design Inspired by Nature: Crystallographic Detection of an Auto-Tailored Protease Inhibitor Template.
    Gall FM; Hohl D; Frasson D; Wermelinger T; Mittl PRE; Sievers M; Riedl R
    Angew Chem Int Ed Engl; 2019 Mar; 58(12):4051-4055. PubMed ID: 30615822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
    Xie XW; Wan RZ; Liu ZP
    ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-7/-13 Inhibitor.
    Fischer T; Riedl R
    Molecules; 2017 Sep; 22(9):. PubMed ID: 32961647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.
    Nara H; Kaieda A; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2017 Jan; 60(2):608-626. PubMed ID: 27966948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
    Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
    Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
    Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.
    Matusiak N; Castelli R; Tuin AW; Overkleeft HS; Wisastra R; Dekker FJ; Prély LM; Bischoff R; van Waarde A; Dierckx RA; Elsinga PH
    Bioorg Med Chem; 2015 Jan; 23(1):192-202. PubMed ID: 25438884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitors.
    Bertran A; Khomiak D; Konopka A; Rejmak E; Bulska E; Seco J; Kaczmarek L; Tarragó T; Prades R
    Bioorg Chem; 2020 Jan; 94():103365. PubMed ID: 31676116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors.
    Khalil HH; El-Sheshtawy MM; Khattab SN; Abu-Serie MM; Shehat MG; Teleb M; Haiba NS
    Bioorg Chem; 2024 Mar; 144():107155. PubMed ID: 38306827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtual Screening on MMP-13 Led to Discovering New Inhibitors Including a Non-Zinc Binding and a Micro Molar One: A Successful Example of Receptor Selection According to Cross-Docking Results for a Flexible Enzyme.
    Ramezani M; Shamsara J
    Comb Chem High Throughput Screen; 2017; 20(8):719-725. PubMed ID: 28814230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Recognition of the Catalytic Zinc(II) Ion in MMP-13: Structure-Based Evolution of an Allosteric Inhibitor to Dual Binding Mode Inhibitors with Improved Lipophilic Ligand Efficiencies.
    Fischer T; Riedl R
    Int J Mol Sci; 2016 Mar; 17(3):314. PubMed ID: 26938528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Structural Evolution of Matrix Metalloproteinase Inhibitors.
    Fischer T; Senn N; Riedl R
    Chemistry; 2019 Jun; 25(34):7960-7980. PubMed ID: 30720221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.